Leukemia and Lymphoma

Detection of Minimal Residual Disease

  • Theodore F. Zipf
  • Dennis A. Johnston

Table of contents

  1. Front Matter
    Pages i-xii
  2. Richard Ratei, Wolf-Dieter Ludwig
    Pages 1-19
  3. Dennis A. Johnston, Theodore F. Zipf
    Pages 53-75
  4. John Moppett, Amos Burke, Christopher Knechtli, Anthony Oakhill, Colin Steward, Nicholas J. Goulden
    Pages 85-96
  5. Letizia Foroni, Forida Y. Mortuza, A. Victor Hoffbrand
    Pages 97-117
  6. Jesús F. San Miguel, María B. Vidriales, Alberto Orfao
    Pages 119-136
  7. Guido Marcucci, Michael A. Caligiuri
    Pages 137-161
  8. Francesco Lo Coco, Daniela Diverio
    Pages 163-178
  9. Nicholas C. P. Cross, Andreas Hochhaus
    Pages 179-199
  10. Apostolia-Marie Tsimberidou, Yunfang Jiang, Richard J. Ford, Fernando Cabanillas, Andreas H. Sarris
    Pages 223-236
  11. Ming-Sheng Lee, Fernando Cabanillas
    Pages 237-242
  12. Theodore F. Zipf, Dennis A. Johnston
    Pages 243-248
  13. Back Matter
    Pages 249-257

About this book


With the detection of the leukemias and lymphomas at levels almost four orders of magnitude below that obtainable by light microcopy, the groundwork has been laid for the development of reliable clinical tools and a redefinition of remission and relapse. In Leukemia and Lymphoma: Detection of Minimal Residual Disease, hands-on experts describe and discuss the minimal residual disease (MRD) methods they have successfully pioneered for these hematological cancers. The techniques range from the use of patient-specific immunophenotypes to identify residual leukemia in patients who are in remission, to a variety of PCR techniques for detecting residual disease and measuring its level. Reverse transcription PCR (RT-PCR) is applied to acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and acute promyelocytic leukemia (APL). Other PCR methods are used for non-Hodgkin's lymphoma and for the monitoring of follicular lymphoma. Additional chapters address the use of real-time quantitative PCR (RQ-PCR), the emergent method of choice, in patients with acute lymphoblastic leukemia (ALL), the evaluation of MRD techniques in clinical trials, and the application of flow cytometry techniques.
Comprehensive and innovative, Leukemia and Lymphoma: Detection of Minimal Residual Disease sets the stage for implementing the new standard detection and quantitation techniques as reliable tools for clinical decision-making, as well as for improved predictions and treatment outcomes.


DNA cell clinical trial leukemia lymphoma stem cell stem cell transplantation transplantation

Editors and affiliations

  • Theodore F. Zipf
    • 1
  • Dennis A. Johnston
    • 2
  1. 1.HoustonUSA
  2. 2.Department of BiomathematicsMD Anderson Cancer CenterHoustonUSA

Bibliographic information